Methotrexate in Retinal Detachment With Proliferative Vitreoretinopathy
NCT ID: NCT07058337
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2024-06-09
2025-06-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
"Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy"
NCT06289205
Visual Outcome of Vitrectomy After Refractive Surgery
NCT05583253
Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencingvitreoretinopathy
NCT04520789
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
NCT02858076
Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage
NCT03637283
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intervention Groups:
1\. Group 1 (PPV Alone): Patients in this group will undergo pars plana vitrectomy (PPV) only.
Group 2 (PPV with Methotrexate): Patients in this group will receive complete PPV along with adjunctive intravitreal methotrexate.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 (PPV Alone)
Patients in this group will undergo pars plana vitrectomy (PPV) only.
parsplana vitrectomy
23 gauge parsplana vitrectomy
Group 2 (PPV with Methotrexate)
Patients in this group will receive complete PPV along with adjunctive intravitreal methotrexate
parsplana vitrectomy
23 gauge parsplana vitrectomy
adjunctive use of Methotrexate
intravitreal methotrexate (200 μg/0.05 ml) at the time of surgery and repeated weekly for four weeks postoperatively
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
parsplana vitrectomy
23 gauge parsplana vitrectomy
adjunctive use of Methotrexate
intravitreal methotrexate (200 μg/0.05 ml) at the time of surgery and repeated weekly for four weeks postoperatively
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with RRD with clinical signs of PVR.
* No history of prior ocular surgeries for RRD or PVR.
Exclusion Criteria
* Individuals with significant systemic illnesses that could influence surgical outcomes.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ehab Mohamed Elsayed Mohamed Saad
Lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ebsar Eye Center
Cairo, Egypt, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Methorexate in PVR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.